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Background: Anabolic androgenic steroids, such as stanozolol, are typically misused by athletes during preparation
for competition. Out-of-competition testing presents a unique challenge in the current anti-doping detection
system owing to logistic reasons. Analysing hair for the presence of a prohibited drug offers a feasible solution for
covering the wider window in out-of-competition testing. To assist in vivo studies aiming to establish a relationship
between drug levels detected in hair, urine and blood, sensitive methods for the determination of stanozolol and
its major metabolite 30-hydroxystanozolol were developed in pigmented hair, urine and serum, using brown
Norway rats as a model system and liquid chromatography tandem mass spectrometry (LC-MS/MS).
Results: For method development, spiked drug free rat hair, blood and urine samples were used. The newly
developed method was then applied to hair, urine and serum samples from five brown Norway rats after treatment
(intraperitoneal) with stanozolol for six consecutive days at 5.0 mg/kg/day. The assay for each matrix was linear
within the quantification range with determination coefficient (r2) values above 0.995. The respective assay was
capable of detecting 0.125 pg/mg stanozolol and 0.25 pg/mg 30-hydroxystanozolol with 50 mg hair; 0.063 ng/mL
stanozolol and 0.125 ng/mL 30-hydroxystanozolol with 100 μL of urine or serum. The accuracy, precision and
extraction recoveries of the assays were satisfactory for the detection of both compounds in all three matrices. The
average concentrations of stanozolol and 30-hydroxystanozolol, were as follows: hair = 70.18 ± 22.32 pg/mg and 13.01 ±
3.43 pg/mg; urine = 4.34 ± 6.54 ng/mL and 9.39 ± 7.42 ng/mL; serum = 7.75 ± 3.58 ng/mL and 7.16 ± 1.97 ng/mL,
respectively.
Conclusions: The developed methods are sensitive, specific and reproducible for the determination of stanozolol and
30-hydroxystanozolol in rat hair, urine and serum. These methods can be used for in vivo studies further investigating
stanozolol metabolism, but also could be extended for doping testing. Owing to the complementary nature of these
tests, with urine and serum giving information on recent drug use and hair providing retrospective information on
habitual use, it is suggested that blood or urine tests could accompany hair analysis and thus avoid false doping results.
Keywords: Anabolic androgenic steroid, Doping, Hair analysis, Urinalysis, Serum analysis, LC-MS/MS* Correspondence: J.Barker@kingston.ac.uk
1School of Pharmacy and Chemistry, Kingston University, Penrhyn Road,
Kingston upon Thames, Surrey KT1 2EE, UK
Full list of author information is available at the end of the article
© 2012 Deshmukh et al.; licensee Chemistry Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Deshmukh et al. Chemistry Central Journal 2012, 6:162 Page 2 of 12
http://journal.chemistrycentral.com/content/6/1/162Background
Laboratory statistics of the World Anti-doping Agency
(WADA) show that anabolic-androgenic steroids (AAS)
account for around 53.6% (average from 2005 to 2010)
of all adverse analytical findings in sports [1-6]. Among
these, stanozolol is one of the most frequently identified
AAS. Stanozolol is a synthetic derivative of the male sex
hormone testosterone. According to ‘The 2013 Prohib-
ition List’ of the WADA code, stanozolol belongs to class
S1.1a and its use is prohibited both in- and out-of-
competition [7]. Doping with stanozolol is suspected if the
urinary concentration of stanozolol and/or its metabolites
exceeds 2 ng/mL [8]. Three of the major metabolites of
stanozolol are reported to be 30-hydroxystanozolol, 4β-
hydroxystanozolol and 16β-hydroxystanozolol (Figure 1),
which are excreted in urine mainly as glucuronide conju-
gates [9]. Amongst these, the urinary level of 30-hydroxys-
tanozolol, post deglucuronidation, is routinely used for
screening stanozolol misuse [8-10].
Since stanozolol and 30-hydroxystanozolol are structur-
ally different from most AAS, they can be more difficult
to detect in urine than other AAS [11], and thus require
bespoke methods. Depending on the dose administered,
once in the body, stanozolol gets rapidly metabolised
and the metabolites are generally detected in urine untilFigure 1 Structures of stanozolol and its major urinary metabolites.ca. 6 days [11]. Thus, urinalysis generally fails to
determine the long term history of an individual’s drug
use [12], which is a major hindrance in cases of
performance-enhancing drugs used in preparation for
competition. Stanozolol, along with other AAS, is a so
called ‘training drug’ which is taken for a prolonged
period, typically in cycles, during preparation, in order
to obtain the desired performance-enhancing effects
[13,14]. Furthermore, urinalysis also fails to distinguish
between chronic use and single, accidental exposure of
drugs [15].
The major elimination and deactivation pathway of
AAS and their phase I metabolites is through glucuro-
nide conjugation (phase II metabolism), mainly catalysed
by the enzyme UGT2B17, followed by excretion in urine
[16-19]. However, inter-individual and inter-ethnic varia-
tions in the prevalence of deletion polymorphism in the
gene coding of the UGT2B17 enzyme have been reported,
which eventually influence the urinary excretion of AAS
and potentially lead to false-negative doping results
[20,21]. It has also been reported that the glucuronidation
activity of UGT2B17 and other UGTs towards AAS is
inhibited by commonly used anti-inflammatory drugs like
diclofenac and ibuprofen, in vitro [22-26]. Common diet-
ary substances such as red wine [27], white tea and green
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in vitro studies. Although the inhibitory effect is yet to be
examined and reported in vivo, these in vitro results indi-
cate that concomitant use of such over-the-counter medi-
cation or common dietary products with AAS may lead to
impaired urinary excretion of AAS and their metabolites.
Considering that such genetic and metabolic variations
may limit the efficacy of urinalysis in testing doping, it
can be suggested that urinalysis, if used as a stand-
alone test, is susceptible to confounding doping results
[11-13,16-21]. Owing to the growing number of doping
cases with AAS [1-6], there is an ever-increasing need
to develop new methods to detect drug doping. The
current anti-doping regime can be reinforced by employing
additional biological samples like blood and hair analysed
in tandem with urine. Since impaired glucuronidation leads
to reduction in the urinary excretion rate of AAS, it can be
assumed that the levels of unconjugated AAS and their
phase I metabolites in the systemic circulation will be
elevated and thus higher levels of AAS and their phase
I metabolites will be available to get incorporated into
hair and other body tissues [21]. Hair analysis has been
used in the past for detecting drug use [29-32] as it pre-
dominantly favours the direct detection of parent AAS
and determines a retrospective history of drug use.
Thus, hair analysis and blood analysis [33] can provide
complementary information to urinalysis to prevent
false doping results.
However, to investigate this option further, in vivo
studies are required to establish a relationship between
the drug levels detected in hair, urine and blood. To
the best of our knowledge, such studies for the deter-
mination of stanozolol and its major metabolite, 30-
hydroxystanozolol in the three matrices together are,
as yet, not reported in the literature. Thus, the aim of
this work was to take a step forward by developing
liquid-chromatography tandem mass spectrometry
(LC-MS/MS) based methods which are capable of de-
termining the concentrations of stanozolol and 30-
hydroxystanozolol in pigmented hair, urine and blood
serum samples of stanozolol-treated rats.
In the past, in vivo studies have been reported where ad-
ministration of a single high dose of stanozolol (60 mg/kg)
to guinea pigs afforded the detection of stanozolol in
hair [34,35], whereas it was not possible to detect 30-
hydroxystanozolol [34]. Since, metabolites are generally
difficult to detect in hair, it is reasonable to assume that
a single-dose treatment may not be sufficient to investi-
gate whether levels of metabolites can be determined in
hair. However, multiple doses of stanozolol along with
sensitive analytical methods can provide this key infor-
mation. Thus, as a preliminary step, a 6 day treatment
period was used in this study to improve the potential
for detecting the metabolites in hair. Athletes typicallyadminister AAS at doses ranging from 3 mg/kg to
25 mg/kg to increase muscle mass, which are 10 to 100
fold higher than the therapeutic doses [36]. Thus, in
line with previous steroid-abuse rat studies [36-39], the
present study was designed with a daily dose of 5.0 mg/
kg for 6 consecutive days, followed by analysing hair,
urine and sera samples using newly developed LC-MS/
MS methods.
Experimental
Chemicals, reagents and consumables
Reference standards for stanozolol, 30-hydroxystanozolol,
30-hydroxystanozolol glucuronide, 30-hydroxystanozolol
D3 and stanozolol D3 were purchased from LGC stan-
dards (Teddington, UK). Sodium hydrogen phosphate
heptahydrate, sodium phosphate monobasic dihydrate,
sodium hydroxide, formic acid, hydrochloric acid, LC-
MS grade water, acetonitrile, methanol, HPLC grade
dichloromethane, pentane, chloroform and ethylacetate
were purchased from Sigma Aldrich (Poole, UK). β-
glucuronidase from E. Coli (Cat. No. 03707598001, Lot
No. 12438921) was purchased from Roche Diagnostics
(Burgess Hill, UK). All chemicals were of analytical-
reagent grade and were used without further purifica-
tion. For the animal experiment, stanozolol, ketamine
(2.5%) and xylazine (Rompun, 2%) were purchased from
Desma (Madrid, Spain), Kőbányai Gyógyszerárugyár
(Budapest, Hungary) and Haver-Lockhart laboratories
(Kansas, US) respectively. A SB C-18 column (2.1 mm,
50 mm, 1.8 μm) and 0.2 μm inline filter was purchased
from Agilent (Stockport, UK). Syringe driven 0.2 μm
PTFE filters were purchased from Millipore (Watford,
UK). Silanised glass inserts were purchased from Capital
Analytical (Leeds, UK). Silanised, amber, glass vials were
purchased from Sigma Aldrich (Poole, UK).
Animals
Male, brown Norway rats were purchased from Charles
River laboratories (Sulzfeld, Germany). Each animal
weighed around 280–340 g and was approximately
5 months old. All animals were kept in an animal house
located in Semmelweis University, Budapest, Hungary.
Animals were housed in groups of three individuals in
standard laboratory cages. Rats were kept in a constant
room temperature environment with an alternating 12-h
light–dark cycle. Food and water were available ad-
libitum.
Administration of stanozolol and sample collection
Five rats kept in standard lab cages under 12/12 light/
dark cycle were administered with stanozolol (in saline)
intra-peritoneally [34], at a dose of 5.0 mg/kg/day for six
consecutive days. The dose of stanozolol selected was in
line with previous steroid studies using rat models [36-39]
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a milligram per kilogram of body weight basis [36,37].
Hair, urine and blood samples were collected on the 7th
day of the study, i.e. one day after stopping the stanozolol
treatment.
The growth rate of rat hair was tested prior to the
treatment regime by shaving the back of the experimen-
tal animals and the sampling protocol was adjusted
accordingly.
Urine was collected by gently pressing the abdomen.
Blood was taken from the tail vein. Blood samples were
left to clot for 45 to 60 minutes and then centrifuged (at
1000 × g for 10 minutes at room temperature) to harvest
serum. Before collecting blood and urine samples, the
animals were anaesthetised with a mixture of ketamine
and xylazine. Two weeks before the experiment, the
entire dorsal surface of the animal was shaved to the
skin with an electric shaver and drug-free control hair
was collected and preserved. Exactly the same dorsal
surface was sampled on the 7th day of the experiment to
avoid any diluting effect of the hair grown before the
stanazolol treatment period. Drug-free blood and urine
samples were also collected before the experiment was
initiated. Serum and urine samples obtained were stored
at −80°C. Hair samples were stored in sealed, clean
envelopes at room temperature. The administration of
stanozolol and sample collection were conducted under
the institutional license of Department of Anatomy,
Histology and Embryology, Semmelweis University,
Budapest, Hungary in accordance with the EC Council
directives on laboratory animals (86/609/EEC). Samples
were analysed in Kingston University.
Sample preparation
Hair samples
Hair samples were initially decontaminated by rinsing
twice with 2 mL dichloromethane for two minutes at
room temperature. After decontamination, hair samples
were allowed to air dry and then pulverised using a ball
mill. Fifty milligrams of decontaminated hair powder
was incubated with 1 mL 1 M sodium hydroxide at 95°C
for 10–15 minutes in the presence of deuterated internal
standards (ISs) stanozolol D3 and 30-hydroxystanozolol
D3. After cooling, the homogenate was neutralised with
1 M hydrochloric acid, followed by addition of 2 mL of
0.2 M phosphate buffer (pH 7.0).
Serum and urine samples
Serum and urine samples were thawed and vortex
mixed. A 100 μL aliquot of each was used for analysis.
Enzymatic hydrolysis of glucuronide conjugates
The enzyme β-glucuronidase was used for the enzymatic
hydrolysis of glucuronide conjugates to determine the totalconcentration (glucuronide conjugated + unconjugated) of
stanozolol and 30-hydroxystanozolol in each matrix (hair,
urine and serum). For this step, and, in a similar manner to
the hair samples, the serum and urine samples were also
neutralised by mixing with 1 mL of 0.2 M phosphate buffer
(pH 7.0). The neutralised solutions of hair, serum and
urine were hydrolysed by incubation with 50 μL of β-
glucuronidase at 50°C for two hours in the presence of
internal standards [9]. After cooling, the samples were
purified by performing liquid–liquid extraction (LLE).Sample purification
LLE was carried out by using a mixture of pentane, chloro-
form and ethylacetate (4 mL in total) in the ratio 3:2:1 v/v/v.
The mixture was vortex mixed for 20 seconds and then
centrifuged at 4000 × g for 20 minutes at 4°C. The or-
ganic layer was transferred into a clean, silanised, glass
vial and evaporated at 40°C using a gentle stream of ni-
trogen gas. The dried residue was reconstituted with
100 μL methanol. The reconstituted solution was fil-
tered through a 0.2 micron PTFE membrane filter, prior
to injecting (3 μL) into the LC-MS/MS system.Liquid chromatographic-tandem mass spectrometry
The analysis of stanozolol and its metabolite 30-
hydroxystanozolol was carried out using an LC-MS/MS
system, which comprised of a 1260 infinity LC system
(Agilent, Wokingham, UK) coupled to a 6430 triple
quadrupole mass spectrometer (Agilent, Wokingham,
UK). The LC system comprised of a binary pump, auto-
matic degasser, column heater and 1290 infinity thermo-
stated autosampler. The analytical column used was a
SB C-18 column (2.1 mm, 50 mm, 1.8 μm), kept in a
column oven at 45°C. A 0.2 micron inline filter was in-
stalled prior to the column to prevent the analytical col-
umn from blocking. Mobile phase solvents comprised of
water with 0.001% v/v formic acid as solvent A and
50:50 mixture of acetonitrile and methanol as solvent B.
The flow rate of mobile phase through the column was
300 μL/min. The gradient flow composition is shown in
Table 1.
The mass spectrometer was equipped with an electro-
spray ionisation (ESI) source, which was operated in
positive ion mode. The protonated molecules, [M +H]+,
of stanozolol (m/z 329.5), 30-hydroxystanozolol (m/z
345.5), stanozolol D3 (m/z 332.5) and 30-hydroxystanozolol
D3 (m/z 348.5) were used as precursor ions for collision
induced dissociation (CID) for MS-MS analysis. The mass
spectrometer was operated in multiple reaction monitoring
(MRM) mode to monitor the precursor ions and the diag-
nostic product ions of each analyte and IS. The MRM tran-
sitions, collision energies and retention times of each
analyte and internal standard are detailed in Table 2.
Table 1 Chromatograms of stanozolol and 30-hydroxystanozolol extracted from (a) hair, (b) urine and (c) serum at
LLOQ concentration levels
LC run time (minutes) Solvent A Water (0.001% formic acid) Solvent B Acetonitrile: methanol (50:50)
0 60 40
1 60 40
2 15 85
5 0 100
6 0 100
7 60 40
15 60 40
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mass spectrometric conditions were applied: capillary
voltage, 4000 V; drying gas temperature, 325°C; drying
gas flow rate, 10 L/min; nebulising gas pressure, 35 psi
and fragmentor voltage of 125 V. The mass spectromet-
ric parameters were optimised using the Masshunter
optimizer software (version B.03.01). The LC-MS/MS
system was controlled by the Masshunter workstation
software (LC/MS data acquisition, version B.03.01).
Method validation
The validation of the analytical methods was performed
according to the Food and Drug Administration (FDA)
guidelines [40], by determining accuracy, precision, lower
limits of quantification (LLOQ), lower limits of detection
(LLOD), linearity, selectivity, and extraction recoveries
[41,42]. Drug-free rat hair, urine and serum samples were
used for method development and validation. Samples for
calibration curves were prepared by spiking known
amounts of stanozolol, 30-hydroxystanozolol and ISs (sta-
nozolol D3 and 30-hydroxystanozolol D3) to drug-free
hair, urine and serum. Quality control (QC) samples were
prepared similarly at three concentration levels (for each
matrix) distributed over the linear range. Calibration
curves were prepared for each matrix by plotting the ana-
lyte to IS ratio against the known concentrations of ana-
lyte in each sample. The analyte to IS ratio for each
analyte was obtained by dividing the peak area of analyte
by the peak area of the IS. Samples for calibration curves
and quality controls were treated in a way similar toTable 2 Retention times, MRM transitions and collision energ
30-hydroxystanozolol D3
Compounds Retention time (min)
Stanozolol 6.0
30-Hydroxystanozolol 5.6
Stanozolol D3 6.1
30-Hydroxystanozolol D3 5.8unknowns. The linearity of the method was investigated
by using linear regression analysis.
The accuracy of each assay was determined by analys-
ing QC samples at three concentration levels in repli-
cates (N = 6, per concentration level) and comparing the
mean calculated values with the respective nominal con-
centration values. Intra-day precision was determined by
measuring 6 replicates per concentration level, on the
same day. Inter-day precision was assessed by analysing
6 replicates per concentration level, on three consecutive
days. Intra-day and inter-day precision of the method
was characterised in terms of relative standard deviation
(RSD, %). The limits of acceptable variability were set at
15% for all the concentrations, except at LLOQ, for
which 20% was accepted. LLOD was defined as the low-
est concentration of the analyte which gave a peak re-
sponse equivalent to three times the background noise
[i.e. signal to noise ratio (S/N) ≥ 3]. LLOQ was defined
as the lowest amount of analyte which gave a peak re-
sponse with a S/N ≥ 10 and which could be measured
with adequate precision and accuracy (RSD less than
20% and an inaccuracy ±20%) [40].
The selectivity of the method was determined by analys-
ing the drug-free samples of hair, urine and serum in repli-
cates and confirming the absence of any detectable peaks
at the retention times of stanozolol, 30-hydroxystanozolol
and ISs. The extraction recovery for each analyte was
determined at three concentration levels by replicate ana-
lysis (N = 6) of blank matrices (urine, serum and hair)
spiked with known concentrations of analytes and ISs andies of stanozolol, 30-hydroxystanozolol, stanozolol D3 and
MRM transitions Collision energy (eV)
329.5 > 81.1 50
329.5 > 121.1 46
345.5 > 97.1 50
345.5 > 121.1 42
332.2 > 81.2 50
348.5 > 97.1 50
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standard peak area ratios obtained after extraction were
then compared with analyte to internal standard peak area
ratios of standard solutions prepared in methanol at the
same final concentrations. To determine matrix effects,
blank hair, urine and serum samples from different ani-
mals were extracted as described above. In order to con-
sider only the matrix effect and not losses during the
extraction procedure, the blank extracts were spiked with
known concentrations of analytes and ISs after the extrac-
tion step, followed by analysis. The resulting peak areas of
stanozolol, 30-hydroxystanozolol and ISs were then com-
pared with the peak areas of standard solutions of stano-
zolol, 30-hydroxystanozolol and ISs at the same theoretical
concentrations.Figure 2 Product ion mass spectra (full scan) of stanozolol and
30-hydroxystanozolol.Results and discussion
Method development
Both stanozolol and 30-hydroxystanozolol were detected
and quantified on the basis of their retention time and
MRM transitions (Table 2). The most abundant product
ions that were monitored for stanozolol were m/z 81.1
and 121.1, whereas for 30-hydroxystanozolol, the most
abundant product ions that were monitored were m/z
97.1 and 121.1. Figure 2 represents the product ions mass
spectra (full scan) of stanozolol and 30-hydroxystanozolol.
Operating the mass spectrometer in MRM mode
enhanced the method selectivity, sensitivity and specificity.
Stanozolol D3 and 30-hydroxystanozolol D3 were used as
internal standards for stanozolol and 30-hydroxystanozolol
respectively. Internal standards were used to compensate
for any: i) ionisation suppression, ii) variations in the in-
strument response from injection to injection and iii) loss
of analytes during sample preparation.
Use of different mobile phase solvents was investigated.
For instance, use of water as solvent A in combination
with methanol or acetonitrile or a mixture of methanol
and acetontrile (50:50) as solvent B was examined. Differ-
ent gradient and isocratic mobile phase compositions
were investigated. Addition of formic acid (0.001% v/v,
0.01% v/v and 0.1% v/v) to solvent A and/or solvent B was
also investigated. Optimum sensitivity and excellent peak
shapes for all analytes and ISs were obtained when water
with formic acid (0.001% v/v) was used as solvent A and a
mixture of acetonitrile and methanol (50:50) was used as
solvent B under the gradient conditions shown in Table 1.
It was observed that when formic acid was added to solv-
ent A and/or solvent B at concentrations ≥ 0.01% v/v,
there was a drastic reduction in the sensitivity of all ana-
lytes and ISs (up to 50%). However, when formic acid was
added only to water (solvent A) at a concentration of
0.001% v/v, there was no effect on the sensitivity and peak
shapes.For hair analysis, alkali digestion was employed for the
extraction of drugs from hair matrix. Alkali digestion
ensures complete dissolution of the hair matrix and
hence it is generally known to give good recoveries of
drugs entrapped in the hair matrix. However, a potential
drawback of complete dissolution of hair is that the
components of hair matrix in solution may interfere
with the analysis. Thus, to reduce the unwanted matrices
that may affect the analysis, sample purification was car-
ried out using LLE. The extraction efficiencies of differ-
ent solvents like pentane, hexane, chloroform, ethyl
acetate and ethanol, and their combinations were inves-
tigated. It was found that a mixture of pentane, chloro-
form and ethyl acetate in the ratio 3:2:1 v/v/v facilitated
maximum recovery of analytes and ISs. Also, owing to
the hair decontamination step employed (using dichloro-
methane), no external interferences were observed. The
LLE step employed was also efficient for the extraction
of stanozolol, 30-hydroxystanozolol and ISs from the
urine and serum samples. Under the analytical conditions
employed, there were no matrix interferences that affected
the analysis of stanozolol and 30-hydroxystanozolol in hair,
urine and serum. The enzymatic hydrolysis of glucuronide
conjugates of stanozolol and 30-hydroxystanozolol was
Figure 3 Chromatograms of stanozolol and 30-hydroxystanozolol extracted from (a) hair, (b) urine and (c) serum at LLOQ
concentration levels.
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Table 4 Extraction recovery results of stanozolol and
30-hydroxystanozolol from hair
Compounds Concentration
(pg/mg)
% Extraction
recovery
(N = 6)
Stanozolol 0.5 (LLOQ) 100.84
2.5 103.53
10 105.39
3-Hydroxystanozolol 0.5 (LLOQ) 88.51
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curonide conjugated plus unconjugated) of stanozolol and
30-hydroxystanozolol could be determined in each matrix
[9]. The conditions employed for enzymatic hydrolysis step
(incubation temperature, time and pH) were optimised
using 30-hydroxystanozolol glucuronide. Complete hydroly-
sis of the glucuronide conjugate was achieved when the pH
of the sample solution was adjusted to 7, followed by incu-
bation with β-glucuronidase (50 μL) at 50°C for 2 hours.2.5 107.99
10 102.64Method validation
The validation results are within the limits set by the FDA
guidelines [40]. The methods were selective and specific
for unambiguous determination of stanozolol and 30-
hydroxystanozolol in all three matrices. Suppression or
enhancement of analyte ionisation owing to co-eluting
components of matrices was not observed. Excellent peak
shape was achieved for stanozolol, 30-hydroxystanozolol, sta-
nozolol D3 and 30-hydroxystanozolol D3. Figure 3 represents
chromatograms of stanozolol and 30-hydroxystanozolol
extracted from hair, urine and serum at LLOQ concentration
levels. Typical calibration curves of stanozolol and 30-
hydroxystanozolol in all three matrices are provided in
Additional file 1.Hair
The assay for hair analysis was linear in the range 0.5 -
400 pg/mg for both stanozolol and 30-hydroxystanozolol.
The determination coefficient (r2) values were found to be
higher than 0.9986 for all calibration curves. The method
was capable of detecting (LLOD) stanozolol and 30-
hydroxystanozolol in hair at concentrations as low as
0.125 pg/mg and 0.25 pg/mg respectively when ca. 50 mg
hair was processed. The LLOQ level of both stanozolol
and 30-hydroxystanozolol was found to be 0.5 pg/mg. The
accuracy, intra-day precision and inter-day precision
results of the assay are detailed in Table 3. The extraction
recoveries of both compounds (at three concentration
levels) from hair are presented in Table 4.Table 3 Accuracy, intra-day precision and inter-day precision
30-hydroxystanozolol in rat hair
Compounds Concentration (pg/mg) Level
Stanozolol 2.5 Low
20 Mediu
100 High
30-Hydroxystanozolol 2.5 Low
20 Mediu
100 HighUrine
The assay for urinalysis was linear in the range 0.125 -
25 ng/mL for stanozolol and 0.25 - 25 ng/mL for 30-
hydroxystanozolol. The determination coefficient (r2)
values were found to be higher than 0.9959 for all runs.
The method was capable of detecting (LLOD) stanozolol
and 30-hydroxystanozolol at concentrations as low as
0.063 ng/mL and 0.125 ng/mL urine respectively, when
only 100 μL aliquot of urine was processed. The LLOQ
levels of stanozolol and 30-hydroxystanozolol were found
to be 0.125 ng/mL and 0.25 ng/mL urine respectively.
Table 5 summarises the accuracy, intra-day precision
and inter-day precision results of the assay. The extrac-
tion recoveries from urine at three concentration levels
are presented in Table 6.Serum
The serum assay showed good linearity within the quanti-
fication range 0.25 - 100 ng/mL for both stanozolol and
30-hydroxystanozolol, with determination coefficient (r2)
values higher than 0.9981. The method was capable of
detecting (LLOD) stanozolol and 30-hydroxystanozolol in
serum at concentrations as low as 0.063 ng/mL and
0.125 ng/mL respectively when only 100 μL aliquot of
serum was processed. The LLOQ level of both stanozolol
and 30-hydroxystanozolol was found to be 0.25 ng/mL.of the assay for detecting stanozolol and
Precision RSD (%) Accuracy (%)
Intra-day Inter-day
3.4 2.8 105.0
m 1.5 1.3 103.4
1.2 2.8 100.7
1.5 4.1 97.3
m 3.6 3.4 101.9
3.8 5.3 100.5
Table 5 Accuracy, intra-day precision and inter-day precision of the assay for detecting stanozolol and
30-hydroxystanozolol in rat urine
Compounds Concentration (ng/mL) Level Precision RSD (%) Accuracy (%)
Intra-day Inter-day
Stanozolol 0.5 Low 10.4 6.3 90.6
2.5 Medium 4.6 7.0 105.6
5 High 4.1 4.0 111.4
30-Hydroxystanozolol 0.5 Low 4.9 6.2 89.7
2.5 Medium 7.1 5.0 109.2
5 High 6.4 5.1 104.2
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results of the assay are detailed in Table 7. The extraction
recoveries are presented in Table 8.
Application of the method to real samples
The developed methods were employed for determining the
total (glucuronide-conjugated plus un-conjugated) concen-
tration of stanozolol and its metabolite 30-hydroxystanozolol
in rat hair, urine and serum samples. Table 9 represents the
average concentrations (three replicates) of stanozolol
and 30-hydroxystanozolol in hair, urine and serum sam-
ples of each rat. The average concentrations of stanozo-
lol and 30-hydroxystanozolol in rat hair were found to
be 70.18 ± 22.32 pg/mg and 13.01 ± 3.43 pg/mg respect-
ively. The average ratio of concentrations of stanozolol
to 30-hydroxystanozolol in hair was found to be 5.38 ±
0.93. Variations observed in the concentration of stano-
zolol and 30-hydroxystanozolol amongst individual ani-
mals could be owing to differences in their metabolic
pattern. Furthermore, difference in the amount of water
consumed by animals can also lead to variations in the
levels of drugs in their body. The results indicate that
stanozolol gets preferentially incorporated in hair rela-
tive to its metabolite 30-hydroxystanozolol. These find-
ings are in agreement with previous reports [32]. In the
past, researchers have found it difficult to detect 30-
hydroxystanozolol in hair. Cirimile et al. reported the
detection of stanozolol in scalp hair of a bodybuilderTable 6 Extraction recovery results of stanozolol and
30-hydroxystanozolol from urine
Compounds Concentration
(ng/mL)
% Extraction
recovery
(N = 6)
Stanozolol 0.125 (LLOQ) 107.87
2.5 111.77
10 109.64
3-Hydroxystanozolol 0.25 (LLOQ) 91.44
2.5 107.92
10 111.82who declared to be a regular user of stanozolol [43].
However, 30-hydroxystanozolol was not detectable in
hair under their analytical conditions. Similarly, in another
study carried out by Shen et al., stanozolol was detectable
in guinea pig hair after administering stanozolol at a single
high dose of 60 mg/kg, whereas, 30-hydroxystanozolol was
not detectable [34]. However, the method presented here
was capable of detecting stanozolol and 30-hydroxystanozolol
in rat hair after administering stanozolol for 6 days at a
dose of 5.0 mg/kg/day that is considered equivalent to
those levels abused by athletes [36-39]. Thieme et al.
have reported a case where both stanozolol and 30-
hydroxystanozolol were detectable in the hair of a
bodybuilder using gas chromatography high resolution
mass spectrometry (GC-HRMS), after sample derivati-
sation [44]. In the past GC-MS and GC-HRMS have been
frequently employed for the detection of AAS [43-46].
The major disadvantage of such technique is that it
requires a laborious and expensive sample derivatisation
step. Generally, the derivatives are unstable and suscep-
tible to thermal decomposition during analysis, thus
affecting the reproducibility of the method. In contrast,
LC-MS/MS normally does not require any additional deri-
vatisation step. Thus, LC-MS/MS can be considered as a
more economical and feasible approach for analysing AAS
[29,30,47].
In urine, the average concentrations of stanozolol and
30-hydroxystanozolol were found to be 4.34 ± 6.54 ng/mL
and 9.39 ± 7.42 ng/mL respectively. The average urinary
ratio of stanozolol concentration to 30-hydroxystanozolol
concentration was found to be 0.37 ± 0.32. The results
indicate that the urinary concentrations of stanozolol
are comparatively lower than 30-hydroxystanozolol, as
expected. However, in serum the average ratio of con-
centrations of stanozolol to 30-hydroxystanozolol was
found to be 1.09 ± 0.37. Thus, suggesting that both
compounds can be detected in serum at similar con-
centration levels and with equal ease.
The results suggest that the newly developed LC-MS/
MS based methods are capable of detecting and quanti-
fying total concentration (glucuronide conjugated plus
Table 7 Accuracy, intra-day precision and inter-day precision of the assay for detecting stanozolol and
30-hydroxystanozolol in rat serum
Compounds Concentration (ng/mL) Level Precision RSD (%) Accuracy (%)
Intra-day Inter-day
Stanozolol 1.25 Low 4.4 3.0 111.0
10 Medium 1.4 1.6 108.4
50 High 1.7 1.4 90.4
30-Hydroxystanozolol 1.25 Low 4.3 6.4 98.0
10 Medium 3.5 3.9 102.3
50 High 4.8 5.3 91.9
Table 9 Concentrations of stanozolol and
30-hydroxystanozolol in rat hair, urine and serum samples
Matrix Animal Stanozolol 30-
Hydroxystanozolol
Ratio
Hair (pg/mg)
1 46.57 ± 0.17 10.96 ± 0.15 4.25
2 47.25 ± 1.07 9.13 ± 0.12 5.18
3 82.58 ± 2.67 16.92 ± 0.37 4.88
4 77.98 ± 1.03 11.72 ± 0.30 6.65
5 96.54 ± 1.02 16.29 ± 0.07 5.93
Mean 70.18 ±
22.32
13.01 ± 3.43 5.38 ±
0.93
Urine (ng/mL)
1 5.20 ± 0.09 13.54 ± 0.43 0.38
2 0.20 ± 0.01 0.36 ± 0.02 0.56
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hydroxystanozolol in hair, urine and serum samples of
brown Norway rats after administering stanozolol for
6 days at a dose (5.0 mg/kg/day), and this is in line with
steroid studies using rat models [36-39]. Future studies
may expand the stanozolol treatment period to 3 or
more weeks to mimic typical athlete use, along with
experimenting with different stanozolol doses and condi-
tions. These newly developed methods can assist in vivo
studies designed to further investigate the metabolism of
stanozolol. Urinalysis can provide information on
whether UGT substrates/inhibitors and deletion poly-
morphism in the UGT2B17 gene reduce the glucuroni-
dation rate (phase II metabolism) of stanozolol and 30-
hydroxystanozolol, as impaired glucuronidation has been
reported to reduce the urinary concentrations of AAS. It
can be assumed that, owing to compromised urinary excre-
tion, the serum levels of unconjugated stanozolol and 30-
hydroxystanozolol can get elevated [21]. Thus, potentially
greater amounts of stanozolol and 30-hydroxystanozolol
will be available to get incorporated in hair. Hence, these
methods can assist in investigating the potential applica-
tion of hair analysis and serum analysis to provide comple-
mentary information when the urinary excretion of
stanozolol and 30-hydroxystanoozlol is impaired.Table 8 Extraction recovery results of stanozolol and
30-hydroxystanozolol from serum
Compounds Concentration
(ng/mL)
% Extraction
recovery
(N = 6)
Stanozolol 0.25 (LLOQ) 113.24
2.5 101.92
10 109.42
3-Hydroxystanozolol 0.25 (LLOQ) 95.36
2.5 111.03
10 105.29Conclusions
To our knowledge, the detection of stanozolol and 30-
hydroxystanozolol in rat hair, urine and serum at such
low concentration levels using LC-MS/MS, has been
reported here for the first time. Using the newly devel-
oped methods presented here, future research can carry
out in vivo studies to further investigate stanozolol3 0.17 ± 0.02 5.07 ± 0.01 0.03
4 0.70 ± 0.01 8.51 ± 2.41 0.08
5 15.41 ± 0.08 19.49 ± 0.22 0.79
Mean 4.34 ± 6.54 9.39 ± 7.42 0.37 ±
0.32
Serum (ng/mL)
1 5.91 ± 0.00 7.25 ± 0.29 0.82
2 4.69 ± 0.01 7.62 ± 0.27 0.62
3 13.01 ± 0.01 8.76 ± 0.67 1.49
4 5.24 ± 0.06 3.81 ± 0.27 1.38
5 9.90 ± 0.03 8.38 ± 0.22 1.18
Mean 7.75 ± 3.58 7.16 ± 1.97 1.09 ±
0.37
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understanding of the array of factors that may confound
urinalysis results. Also, these methods can be extended
by analysing human hair, urine and serum samples in
tandem to provide a pattern of drug use and this can be
useful for testing doping with stanozolol and other com-
monly abused AAS. Hair can provide retrospective infor-
mation on an individual’s drug use and this can be used
in out-of-competition testing. However, information of
current drug-use, if important, can be obtained by urine
and blood serum analyses. Thus, when the three tests
are used in combination, useful information on an indi-
vidual’s drug use can be obtained and false doping
results can be prevented.
Additional file
Additional file 1: Figure S1. Calibration curves of stanozolol and 30-
hydroxystanozolol in (a) hair, (b) urine and (c) serum.
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